Mathur, Vandana S.
Wesson, Donald E.
Tangri, Navdeep
Li, Elizabeth
Bushinsky, David A.
Article History
Received: 22 September 2021
Accepted: 28 January 2022
First Online: 25 February 2022
Declarations
:
: The protocol was approved by Copernicus Group Independent Review Board and other institutional review boards/ethics committees for each participating site and each patient gave their written informed consent prior to participating in the study. All experimental protocols were approved by a named institutional and/or licensing committee. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: VSM, DEW, NT, EL and DAB were paid consultants to Tricida, Inc. in connection with the development of this manuscript. VSM, DEW, NT and DAB are members of advisory boards at Tricida, Inc. and report consultancy and personal fees from Tricida, Inc. VSM is listed on patents related to work for Tricida, and reports stock or stock options in Tricida. VSM reports additional consulting fees from Tricida, Equillium, Myovant, Rigel, Corvidia, Acuta, Frazier, Intarcia, PTC Bio and Sanifit outside the submitted work. DAB reports stock and stock options from Tricida during and outside this work. DAB was the lead investigator for the phase 1/2 study of veverimer (TRCA-101) sponsored by Tricida and is on the advisory board for the ongoing VALOR-CKD post-marketing study sponsored by Tricida. DAB also reports consulting fees from Amgen, Sanofi/Genzyme, Fresenius/Relypsa/Vifor, personal fees as a medical advisory board member from Sanifit, speaker fees from Sanofi/Genzyme and stock ownership in Amgen and past stock ownership in Relypsa, all outside this work. DAB reports grant support from the National Institutes of Health and Renal Research Institute, both outside this work.